DRUG SAFETY: FDA Has Faced Persistent Challenges Overseeing Foreign Drug Manufacturing.

The article focuses on the challenges faced by the Food and Drug Administration (FDA) in overseeing drugs manufactured overseas, highlighting weaknesses in oversight, the impact of the COVID-19 pandemic on inspections, and persistent vacancies in the FDA's foreign inspection workforce. Topics include FDA's struggle with foreign drug oversight, the influence of COVID-19 on inspection practices, and the ongoing issue of understaffing in FDA's foreign inspection teams.